The Safety of HMG-CoA Reductase Inhibitors in Special Populations at High Cardiovascular Risk
The DOI matches its Crossref record; 281 of the 286 references it cites were found in a registry or an index.
Abstract
Controlled clinical studies and clinical experience over many years have proven that virtually all patients benefit from lipid-lowering therapy with statins, even those with normal LDL cholesterol levels. Several recent large outcome trials have further demonstrated the clinical benefits and safety of statins in patients with a wide-range of high risks for cardiovascular disease. Those patients at highest absolute cardiovascular risk generally have the most to gain from statin therapy. A variety of statins are available to lower plasma lipids to guideline levels, but all differ in their pharmacokinetic properties, drug interaction profiles, and risk of myotoxicity. This has been highlighted by the withdrawal of cerivastatin from the market as a result of serious safety concerns. This review examines the safety and effectiveness of statins in special populations at high risk of cardiovascular disease-patients with coronary heart disease, dyslipidaemia, diabetes, hypertension, nephrotic disease, HIV, organ transplant patients and the elderly-with a focus on clinically relevant differences in the properties of individual statins that may influence the risk of drug interactions and side effects.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Several factors including female sex, ethnicity, multisystem disease, and small body frame predispose to SAMS (see Box 1), with the presence of an increasing number of factors associated with greater risk.9,30,32–34”
Citations
Cites
Grundy, S. M., Bilheimer, D. W., Chait, A., Clark, L. T., Denke, M. A., Havel, R. J., Hazzard, W. R., Hulley, S. B., Hunninghake, D. B., Kreisberg, R. A., et al. (1993) · JAMA · doi:10.1001/jama.269.23.3015 · Cited by 27,947
Expert Panel on Detection, E. (2001) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.285.19.2486 · Cited by 26,011
OLSSON, A. G., McMurray, J. J. V., Thorgeirsson, G., Spaulding, C. M., Slattery, J., Pyörälà, K., Færgeman, O., Wright, R. S., Berg, K. M., Wilhelmsen, L., et al. (1994) · The Lancet · Cited by 8,467
Prevention of Coronary Heart Disease with Pravastatin in Men with Hypercholesterolemia
Shepherd, J., Cobbe, S. M., Ford, I., Isles, C. G., Lorimer, A. R., Macfarlane, P. W., McKillop, J. H., & Packard, C. J. (1995) · New England Journal of Medicine · doi:10.1056/nejm199511163332001 · Cited by 7,449
Sacks, F. M., Pfeffer, M. A., Moye, L. A., Rouleau, J. L., Rutherford, J. D., Cole, T. G., Brown, L., Warnica, J. W., Arnold, J. M. O., Wun, C.-C., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199610033351401 · Cited by 7,439
(1998) · New England Journal of Medicine · doi:10.1056/nejm199811053391902 · Cited by 5,261
Downs, J. R., Clearfield, M., Weis, S., Whitney, E., Shapiro, D. R., Beere, P. A., Langendorfer, A., Stein, E. A., Kruyer, W., Gotto, Jr., et al. (1998) · JAMA · doi:10.1001/jama.279.20.1615 · Cited by 5,236
Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents
(1998) · Annals of Internal Medicine · doi:10.7326/0003-4819-128-12_part_2-199806151-00003 · Cited by 5,209
Stamler, J., Vaccaro, O., Neaton, J. D., Wentworth, D., & The Multiple Risk Factor Intervention Trial Research Group (1993) · Diabetes Care · doi:10.2337/diacare.16.2.434 · Cited by 4,063
Research works printed but not linked: 10
- Farmer JA,Torre-Amione G. Comparative tolerability of the HMG-CoAreductase inhibitors. Drug Saf 2000; 108: 351-352.
- Shek A,Ferrill MJ. Statin-fibrate combination therapy. Ann Pharmacother 2001; 35: 908-917. · doi:10.1345/aph.10315 · Paper page
- Kanathur N,Mathai MG,Byrd RP Jr, et al. Simvastatindiltiazem drug interaction resulting in rhabdomyolysis and hepatitis. Tenn Med 2001; 94: 339-341.
- Lee AJ,Maddix DS. Rhabdomyolysis secondary to a drug interaction between simvastatin and clarithromycin. Ann Pharmacother 2001; 35: 26-31. · doi:10.1345/aph.10177 · Paper page
- Thompson GR. Poor responders to statins:Apotential target for stanol esters. Eur Heart J Suppl 1991; 1(Suppl S): S114-S117.
- Gruer PJ,Vega JM,Mercuri MF,Dobrinska MR,Tobert JA. Concomitant use of cytochrome P450 3A4 inhibitors and simvastatin. Am J Cardiol 1999; 84: 811-815. · DOI
- Peces R,Pobes A. Rhabdomyolysis associated with concurrent use of simvastatin and diltiazem. Nephron 2001; 89: 117-118. · DOI · Paper page
- Regazzi MB,Iacona I,Campana C, et al. Altered disposition of pravastatin following concomitant drug therapy with cyclosporinAin transplant recipients. Transplant Proc 1993; 25: 2732-2734.
- Rozenbaum W,Molina JM,Delfraissy JF, et al. Improvement of lipodystrophy in HIV-1 infected subjects switching from 2NRTI/PI to 2NRTI/abacavir (French substudy, CNA30017). 7th Conference on Retroviruses and Opportunistic Infections; Jan. 3-Feb. 2, 2000; San Francisco, California. Abstract 47.
- Fichtenbaum C,Gerber J,Rosenkranz S, et al. Pharmacokinetic interactions between protease inhibitors and selected HMG-CoA reductase inhibitors. Presented at the 7th Conference on Retroviruses and Opportunistic Infections. Jan. 30-Feb. 2, 2000; San Francisco, California.
Cited by
Stroes, E. S., Thompson, P. D., Corsini, A., Vladutiu, G. D., Raal, F. J., Ray, K. K., Roden, M., Stein, E., Tokgözoğlu, L., Nordestgaard, B. G., et al. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehv043 · Cited by 1,443
“9,30,32–34 Additionally, pharmacokinetic drug–drug interactions (DDIs) that increase statin exposure increase the risk of statin-associated myop-athy (Box 2).”
Self-citationSafety of Statins: Focus on Clinical Pharmacokinetics and Drug Interactions
Bellosta, S., Paoletti, R., & Corsini, A. (2004) · Circulation · doi:10.1161/01.cir.0000131519.15067.1f · Cited by 578
Self-citationClinical Perspectives of Statin-Induced Rhabdomyolysis
Antons, K. A., Williams, C. D., Baker, S. K., & Phillips, P. S. (2006) · The American Journal of Medicine · doi:10.1016/j.amjmed.2006.02.007 · Cited by 238
“Risk stratification based on these accepted risks has been outed as a means of accounting for most serious rhabdoyolysis cases.(13,20,38,39) Yet, statin-induced rhabdomyolyis may develop even when accepted risks are avoided, and etter definition of risk groups is needed.”
BackgroundMason, R. P., Walter, M. F., Day, C. A., & Jacob, R. F. (2005) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2005.06.008 · Cited by 160
The nephrotoxic effects of HAART
Izzedine, H., Harris, M., & Perazella, M. A. (2009) · Nature Reviews Nephrology · doi:10.1038/nrneph.2009.142 · Cited by 156
“Furthermore, many cases of rhabdomyolysis in patients with HIV taking both HAART and statin therapy have been reported”
BackgroundVuppalanchi, R., Chalasani, N., & Teal, E. (2005) · The American Journal of the Medical Sciences · doi:10.1097/00000441-200502000-00002 · Cited by 133
The Role of Structure and Biophysical Properties in the Pleiotropic Effects of Statins
Murphy, C., Deplazes, E., Cranfield, C. G., & Garcia, A. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21228745 · Cited by 127
Statin-induced myositis: a commonly encountered or rare side effect?
Mukhtar, R., & Reckless, J. P. D. (2005) · Current Opinion in Internal Medicine · doi:10.1097/01.mol.0000188414.90528.71 · Cited by 117
Binding Thermodynamics of Statins to HMG-CoA Reductase
Carbonell, T., & Freire, E. (2005) · Biochemistry · doi:10.1021/bi050905v · Cited by 101
Statin drug interactions and related adverse reactions
Bellosta, S., & Corsini, A. (2012) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2012.712959 · Cited by 111
“Finally, it is also important to consider other clinical and pathophysiological conditions that make the patients more sensitive to statin-induced risk of myopathy such as age, gender, diabetes, hypothyroidism and transplanted patients [47].”
BackgroundSelf-citationMyotoxicity associated with lipid-lowering drugs
Baer, A. N., & Wortmann, R. L. (2006) · Current Opinion in Rheumatology · doi:10.1097/bor.0b013e328010c559 · Cited by 103
Effects of Cholesterol-Lowering Statins on the Aqueous Humor Outflow Pathway
Song, J., Deng, P., Stinnett, S. S., Epstein, D. L., & Rao, P. V. (2005) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.04-0776 · Cited by 97
Prevalence and risk factors of muscle complications secondary to statins
El‐Salem, K., Ababneh, B., Rudnicki, S., Malkawi, A., Alrefai, A., Khader, Y., Saadeh, R., & Saydam, M. (2011) · Muscle & Nerve · doi:10.1002/mus.22205 · Cited by 83
Micale Foody, J., Rathore, S. S., Galusha, D., Masoudi, F. A., Havranek, E. P., Radford, M. J., & Krumholz, H. M. (2006) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.2005.00635.x · Cited by 80
“Because all statins undergo metabolism by the cytochrome P450 isoenzyme system to varying degrees, the potential for drug interactions is increased, although side effects occurred in only 3% of patients concurrently taking medications that could potentially interact.(29) Given the potential side effects of therapy,(30…”
BackgroundAwad, K., Șerban, M.-C., Penson, P. E., Mikhailidis, D. P., Toth, P. P., Jones, S. R., Rizzo, M., Howard, G., Lip, G. Y. H., & Banach, M. (2017) · Journal of clinical lipidology · doi:10.1016/j.jacl.2017.06.001 · Cited by 82
Simvastatin reduces ergosterol levels, inhibits growth and causes loss of mtDNA in Candida glabrata
Westermeyer, C., & Macreadie, I. G. (2007) · FEMS Yeast Research · doi:10.1111/j.1567-1364.2006.00194.x · Cited by 73
Appropriateness of statin prescription in the elderly
Ruscica, M., Macchi, C., Pavanello, C., Corsini, A., Sahebkar, A., & Sirtori, C. R. (2018) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2017.12.011 · Cited by 65
Self-citationKohli, R., Klein, R. S., Schoenbaum, E. E., Anastos, K., MINKOFF, H. L., & Sacks, H. S. (2006) · Journal of Urban Health · doi:10.1007/s11524-005-9005-6 · Cited by 63
Jacobson, T. A. (2006) · Drug Safety · doi:10.2165/00002018-200629050-00005 · Cited by 60
The influence of statin characteristics on their safety and tolerability
De Angelis, G. (2004) · International Journal of Clinical Practice · doi:10.1111/j.1368-5031.2004.00355.x · Cited by 45
Statin Regulation of CYP3A4 and CYP3A5 Expression
Willrich, M. A. V., Hirata, M. H., & Hirata, R. D. C. (2009) · Pharmacogenomics · doi:10.2217/pgs.09.42 · Cited by 54
Renal transplantation in patients with HIV
Frassetto, L. A., Tan-Tam, C., & Stock, P. G. (2009) · Nature Reviews Nephrology · doi:10.1038/nrneph.2009.140 · Cited by 53
“Combination treatment of statins with other lipid-lowering agents, such as fibrates, could increase the risk of myotoxic effects”
Statins Could Be Used to Control Replication of Some Viruses, Including HIV-1
Gilbert, C., Bergeron, M., Méthot, S., Giguère, J.-F., & Tremblay, M. J. (2005) · Viral Immunology · doi:10.1089/vim.2005.18.474 · Cited by 47
“Unlike their antiviral effects, pharmacokinetic interactions between statins and drugs used for HAART have been studied in great details (28,31,48,117).”
BackgroundInteraction of statins with phospholipid bilayers studied by solid-state NMR spectroscopy
Galiullina, L. F., Scheidt, H. A., Huster, D., Aganov, A. V., & Klochkov, V. V. (2018) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2018.12.013 · Cited by 52
Recommendations for Managing Drug–Drug Interactions with Statins and HIV Medications
Wiggins, B. S., Lamprecht, D. G., Page, R. L., II, & Saseen, J. J. (2017) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-017-0222-7 · Cited by 45
Genomic and non-genomic interactions of PPARα with xenobiotic-metabolizing enzymes
Barbier, O., Fontaine, C., Fruchart, J., & Staels, B. (2004) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2004.07.007 · Cited by 41
HMG-CoA reductase inhibitors (statins) use and risk of non-Hodgkin lymphoma in HIV-positive persons
Chao, C., Xu, L., Abrams, D. I., Towner, W. J., Horberg, M. A., Leyden, W. A., & Silverberg, M. J. (2011) · AIDS · doi:10.1097/qad.0b013e328349c67a · Cited by 37
“Drug–drug interaction between statins, antiretroviral drugs and certain antiinfection treatments have also been documented [39].”
Interaction of different statins with model membranes by NMR data
Galiullina, L. F., Aganova, O. V., Анварович, Л. И., Musabirova, G., Aganov, A. V., & Klochkov, V. V. (2016) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2016.12.006 · Cited by 37
Treatment of dyslipidemia in kidney transplantation
Ponticelli, C. E., Arnaboldi, L., Moroni, G. L., & Corsini, A. (2020) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2020.1732921 · Cited by 34
Self-citationDyslipidemia in Renal Transplant Recipients
Chmielnicka, K., Heleniak, Z., & Dębska-Ślizień, A. M. (2022) · Transplantology · doi:10.3390/transplantology3020020 · Cited by 29
Efficacy of Drug Therapy in the Secondary Prevention of Cardiovascular Disease and Stroke
Fletcher, G. F., Bufalino, V. J., Costa, F., Goldstein, L. B., Jones, D., Smaha, L. A., Smith, S. C., & Stone, N. J. (2007) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2007.02.001 · Cited by 29
Drug–drug interaction with statins
Corsini, A., & Bellosta, S. (2008) · Expert Review of Clinical Pharmacology · doi:10.1586/17512433.1.1.105 · Cited by 29
Self-citationZaborowska, M., Broniatowski, M., Wydro, P., Matyszewska, D., & Bilewicz, R. (2020) · Journal of Molecular Liquids · doi:10.1016/j.molliq.2020.113570 · Cited by 27
Pearson, T. A., Denke, M. A., McBride, P. E., Battisti, W. P., Brady, W. E., & Palmisano, J. J. (2005) · The American Journal of Geriatric Pharmacotherapy · doi:10.1016/j.amjopharm.2005.12.009 · Cited by 27
Zaborowska, M., Broniatowski, M., Fontaine, P., Bilewicz, R., & Matyszewska, D. (2023) · The Journal of Physical Chemistry B · doi:10.1021/acs.jpcb.3c02574 · Cited by 24
HIV Therapies and the Kidney: Some Good, Some Not So Good?
Ryom, L., Mocroft, A., & Lundgren, J. D. (2012) · Current HIV/AIDS Reports · doi:10.1007/s11904-012-0110-3 · Cited by 22
Statin-associated muscle symptoms EAS Consensus Panel paper focuses on this neglected patient group
Stock, J. K. (2015) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2015.06.049 · Cited by 21
“These may include the use of high-dose statin therapy, polypharmacy, and drugedrug interactions, such as those involving gemfibrozil, macrolides, azole antifungal agents, protease inhibitors and immunosuppressive drugs), as well as inhibitors of cytochrome P450 isoenzymes, organic anion transport protein 1B1 [OATP 1B1…”
BackgroundZaborowska, M., Dziubak, D., Matyszewska, D., & Bilewicz, R. (2021) · Electrochimica Acta · doi:10.1016/j.electacta.2021.138514 · Cited by 19
Fellström, B., Abedini, S., Holdaas, H., Jardine, A. G., Staffler, B., Gimpelewicz, C. R., & the Assessment of Lescol in Renal Transplantation (ALERT) study group (2006) · Clinical Transplantation · doi:10.1111/j.1399-0012.2006.00555.x · Cited by 19
“In addition, renal transplant recipients require lifelong therapy with immunosuppressive drugs, in addition to treatments for other concomitant conditions, and are therefore at high risk of drug interactions that may increase systemic exposure and toxicity of statins (20).”
BackgroundThe under-use of statin in type 2 diabetic patients attending diabetic clinics in Italy
Avogaro, A., Guida, P., Giorda, C. B., Mannucci, E., Medea, G., Comaschi, M., Velussi, M., Armienti, G., & Zucchetti, R. (2006) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2005.12.001 · Cited by 18
Galiullina, L. F., Musabirova, G., Анварович, Л. И., Aganov, A. V., & Klochkov, V. V. (2018) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2018.04.012 · Cited by 16
New-onset diabetes after transplantation
Wheeler, D. C., & Krentz, A. J. (2007) · British Journal of Hospital Medicine · doi:10.12968/hmed.2007.68.4.190 · Cited by 16
Statin-Related Muscle Complaints: An Underestimated Risk
Corsini, A. (2005) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-005-6352-1 · Cited by 16
“Rhabdomyolysis is often characterized by marked elevations of CK levels to >100 times the ULN, and is accompanied by myoglobinuria, myoglobinaemia, and evidence of target organ damage, such as decreased renal function or acute renal failure [6].”
BackgroundInfluentialSelf-citationEstimating localization of various statins within a POPC bilayer
Kuba, J. O., Yu, Y., & Klauda, J. B. (2021) · Chemistry and Physics of Lipids · doi:10.1016/j.chemphyslip.2021.105074 · Cited by 14
Scharnagl, H., Vogel, M., Abletshauser, C., Freisinger, F., Stojaković, T., & März, W. (2006) · Cardiology · doi:10.1159/000093200 · Cited by 14
“The time of administration of therapy has important implications for patient compliance. Patients treated with statins are frequently receiving multiple medications and compliance is known to deteriorate with increasing regimen complexity [ ,”
BackgroundShaw, S. M., Najam, O., Khan, U. A., Yonan, N. A., Williams, S. G., & Fildes, J. E. (2009) · Transplant Immunology · doi:10.1016/j.trim.2009.03.001 · Cited by 14
Modulation of Phospholipid Bilayer Properties by Simvastatin
Teo, R. D., & Tieleman, D. P. (2021) · The Journal of Physical Chemistry B · doi:10.1021/acs.jpcb.1c03359 · Cited by 13
Zaborowska, M., Matyszewska, D., & Bilewicz, R. (2022) · Langmuir · doi:10.1021/acs.langmuir.2c02115 · Cited by 13
New‐onset diabetes after transplantation
Krentz, A. J., & Wheeler, D. C. (2006) · Practical Diabetes · doi:10.1002/pdi.887 · Cited by 13
Localized Rhabdomyolysis After Exertion in a Cardiac Transplant Recipient on Statin Therapy
Biggs, M. J. P., Bonser, R. S., & Cram, R. W. (2006) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2005.09.009 · Cited by 12
Effects of Statin Combinations on Zika Virus Infection in Vero Cells
Españo, E., & Kim, J.-K. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics15010050 · Cited by 11
“On the other hand, FLU is believed to have a lower muscular penetration based on lower reports of rhabdomyolysis [37].”
BackgroundThe use of statins in optimising reduction of cardiovascular risk: focus on fluvastatin
Corsini, A. (2004) · International Journal of Clinical Practice · doi:10.1111/j.1368-5031.2004.00154.x · Cited by 11
Self-citationRosuvastatin in Elderly Patients
Davidson, M. H. (2007) · Drugs & Aging · doi:10.2165/00002512-200724110-00005 · Cited by 10
Corsini, A., & Holdaas, H. (2005) · Renal Failure · doi:10.1081/jdi-200056623 · Cited by 10
Self-citationDiop, A., Sirois, C., Guertin, J. R., Schnitzer, M. E., Candas, B., Cossette, B., Poirier, P., Brophy, J. M., Mésidor, M., Blais, C., et al. (2023) · Statistical Methods in Medical Research · doi:10.1177/09622802231202384 · Cited by 9
Human immunodeficiency virus and renal transplantation
Dinavahi, R. V., Mehrotra, A., Murphy, B. T., & Huprikar, S. S. (2009) · Kidney International · doi:10.1038/ki.2009.184 · Cited by 9
Diabetes and Coronary Heart Disease
McMahon, G. T. (2011) · Springer eBooks · doi:10.1007/978-1-4614-1475-9_27 · Cited by 8
Primary Care of the Transplant Patient
Hasley, P. B., & Arnold, R. M. (2010) · The American Journal of Medicine · doi:10.1016/j.amjmed.2009.06.034 · Cited by 7
Feldman, H. A., Zuber, K., & Davis, J. S. (2017) · Physician Assistant Clinics · doi:10.1016/j.cpha.2017.06.004 · Cited by 5
Анварович, Л. И., Galiullina, L. F., Musabirova, G., Aganova, O. V., Kim, Z. F., Aganov, A. V., & Klochkov, V. V. (2017) · Rational Pharmacotherapy in Cardiology · doi:10.20996/1819-6446-2017-13-2-256-262 · Cited by 5
Ma, T., Huo, F., Zhang, Y., Ma, K., Chao, J., & Yin, C. (2019) · Spectrochimica Acta Part A Molecular and Biomolecular Spectroscopy · doi:10.1016/j.saa.2019.117987 · Cited by 5
Subramanian, T., Subramanian, K. L., Sunkara, M., Onono, F. O., Morris, A. J., & Spielmann, H. P. (2013) · Journal of Labelled Compounds and Radiopharmaceuticals · doi:10.1002/jlcr.3049 · Cited by 5
Zhu, K., Jin, Y., Liu, W., Wen, C., Zheng, X., Li, Z., Chen, Y., Niu, Y., Pan, W., Jiang, Y. D., et al. (2025) · Kidney & Blood Pressure Research · doi:10.1159/000545032 · Cited by 4
“The pathogenic mechanisms of posttransplantation dyslipidemia were multifaceted [24, 25].”
Politerapia e polifarmacia nell’anziano con scompenso cardiaco cronico
Ferrara, N., Terrosu, P., Zuccalà, G., & Corsini, A. (2013) · Giornale Ialiano di Cardiologia · doi:10.1714/1261.13940 · Cited by 3
Self-citationNew-Onset Diabetes after Kidney Transplantation: Diagnosis, Risk Factors, and Management
Bulum, T., Prkačin, I., & Duvnjak, L. S. (2020) · Acta Clinica Croatica · doi:10.20471/acc.2021.60.s1.13 · Cited by 3
Dyslipidemias in the older subject: features,significance and treatment dilemmas
Vigna, G. B., Zuliani, G., & Fellin, R. (2011) · Clinical Lipidology · doi:10.2217/clp.11.20 · Cited by 3
Oxidatively Modified Low-Density Lipoproteins and Thrombosis
Shen, G. X. (2006) · Springer eBooks · doi:10.1007/0-387-36279-3_8 · Cited by 3
“seen in IHD or diabetic patients with normal cholesterol levels [ 99 ].”
BackgroundAcute coronary syndromes in patients with renal disease: What are the issues?
Panetta, C. J., Herzog, C. A., & Henry, T. D. (2006) · Current Cardiology Reports · doi:10.1007/s11886-006-0062-6 · Cited by 3
“Management of lipids in the setting of CKD is difficult, as dialysis is associated with increased prevalence of myalgias and elevated creatine phosphokinase in conjunction with lipid-lowering medications [ 29 ].”
BackgroundYoshida, H. (2007) · Rinsho yakuri/Japanese Journal of Clinical Pharmacology and Therapeutics · doi:10.3999/jscpt.38.35 · Cited by 3
The Pros and Cons of Lipid Lowering in Octogenarians: Clinical Decision Making
Agostini, J. V., & Foody, J. M. (2005) · Aging Health · doi:10.2217/1745509x.1.1.77 · Cited by 2
“Because the majority of statins undergo metabolism by the cytochrome P450 isoenzyme system, the potential for drug interactions is high, although side effects occurred in only 3–10% of patients concurrently taking medications that could potentially interact [25].”
BackgroundStatins in chronic liver disease
Gigante, A. (2013) · Prevention & Research · doi:10.11138/pr/2013.2.2.040 · Cited by 1
Tocci, G., Francione, V., Sciarretta, S., & Volpe, M. (2005) · High Blood Pressure & Cardiovascular Prevention · doi:10.2165/00151642-200512030-00005 · Cited by 1
Néphrotoxicité des antirétroviraux autres que le ténofovir
Loens, C., Amet, S., Bagnis, C. I., Deray, G., & Tourret, J. (2018) · Néphrologie & Thérapeutique · doi:10.1016/j.nephro.2017.12.001 · Cited by 1
Ferrara, N., Corbi, G., Komici, K., & Rengo, G. (2017) · Springer eBooks · doi:10.1007/978-3-319-43468-1_6 · Cited by 1
Rhabdomyolysis and Diabetes: A Mitochondrial Connection
Wubben, D. P., Bruns, C. M., & Seeger, S. K. (2007) · Endocrine Practice · doi:10.4158/ep.13.3.313 · Cited by 1
市販後に分かる薬の安全性と最近の撤退薬 4.スタチン類―Cerivastatinの撤退から学ぶこと
Yoshida, H. (2009) · Rinsho yakuri/Japanese Journal of Clinical Pharmacology and Therapeutics · doi:10.3999/jscpt.40.22 · Cited by 1
Efeitos de hipolipemiantes sobre a expressão de CYP3A4 e CYP3A5 in vitro e in vivo
Willrich, M. A. V. (2011) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.9.2011.tde-12092012-150610
Willrich, M. A. V. (2006) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/d.9.2006.tde-05022007-132823
REVERSAL and PROVE-IT: Are clinically oriented trials really better than “pure” scientific studies?
Cicero, A. F. G., & Gaddi, A. V. (2005) · International Journal of Cardiology · doi:10.1016/j.ijcard.2004.07.018
Towards companion diagnostics for the management of statin therapy
Viljoen, A., & Wierzbicki, A. S. (2009) · Expert Opinion on Medical Diagnostics · doi:10.1517/17530050903222254
Seguridad de las estatinas en el paciente con insuficiencia renal
Castelao, A. M. (2005) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/s0214-9168(05)73373-8
Potential New Therapeutic Agents: Effects on HIV Replication and Viral Escape
Piñas, G. M. (2009) · TDX (Tesis Doctorals en Xarxa)
L'IMPIEGO DELLE STATINE NEL PAZIENTE EPATOPATICO CRONICO
AMOROSO, D., Barbano, B., Dorelli, B., Mario, F. D., & Amoroso, A. (2013)
Bellosta, S., Paoletti, R., & Corsini, A. (2013) · CRC Press eBooks · doi:10.3109/9781420019667-16
Self-citationBibi, R. (2018) · Pure and Applied Biology · doi:10.19045/bspab.2018.70082
Current awareness: Pharmacoepidemiology and drug safety
(2004) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.916
Bellosta, S., Paoletti, R., & Corsini, A. (2006) · Fundamental and clinical cardiology · doi:10.3109/9781420019667.010
Self-citationEstimation de l'effet causal des groupes de trajectoires d'un traitement sur une issue
Diop, A. (2023) · Corpus Université Laval (Université Laval)
Metadata
- Authors
- Corsini, A.
- Affiliations
- University of Milan (IT)
- Corresponding author
- Corsini, Alberto
- ORCID
- Corsini, Alberto
- Venue
- Cardiovascular Drugs and Therapy
- Published
- 2003-05
- Volume
- 17
- Issue
- 3
- Pages
- 265-285
- ISSN
- 0920-3206 (ISSN-L)
- 1573-7241
- OpenAlex
- W2191544621
- Cited by
- 82
- References
- 286
- Citations by year
- 2025: 1 · 2023: 2 · 2022: 3 · 2021: 3 · 2020: 3 · 2019: 1 · 2018: 4 · 2017: 4 · 2016: 1 · 2015: 2 · 2013: 5 · 2012: 2
- FWCI
- 1.88
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springernature.com/gp/researchers/text-and-data-mining (tdm)
- www.springernature.com/gp/researchers/text-and-data-mining (vor)
- Locations
- Cardiovascular Drugs and Therapy (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
- Keywords
- statins, drug safety, high cardiovascular risk, lipid-lowering therapy, drug interactions, myotoxicity, coronary artery disease, dyslipidemia, diabetes mellitus, hypertension, nephrotic syndrome, HIV, transplant recipients, elderly patients, statin pharmacokinetics
- MeSH terms
- Aged, Aged, 80 and over, Cardiovascular Diseases, Clinical Trials as Topic, Coronary Disease, Diabetes Mellitus, Type 2, Humans, Hyperlipidemias, Hypertension, Kidney Failure, Chronic, Rhabdomyolysis, Transplantation, HIV-1, HIV Infections, Hydroxymethylglutaryl-CoA Reductase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.